Antibodies
16 February 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)11 February 2011
Positive TB-402(Anti-Factor VIII Antibody) Phase II Data Published in Journal of Thrombosis and Haemostasis11 February 2011
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)9 February 2011
Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody9 February 2011
Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement for Elan’s Antibody-Based Therapeutics Pipeline8 February 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer7 February 2011
Helix BioPharma Corp. Receives FDA IND Approval to Conduct a U.S. Phase I Clinical Study With Its Lung Cancer Drug Candidate L-DOS474 February 2011
Enbrel (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis4 February 2011
Journal of Clinical Oncology Publishes Clinical Trial Results of VELCADE Combination in Aggressive Subtypes of Non-Hodgkin Lymphoma3 February 2011
AVEO Pharmaceuticals Receives USAN Name for Novel, Internally Discovered Anti-HGF/c-MET Pathway Antibody2 February 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab1 February 2011
APEIRON ACQUIRES RIGHTS FOR A PHASE II BIOLOGIC AGAINST NEUROBLASTOMA AND OTHER CANCERS FROM MERCK KGAA, GERMANY31 January 2011
MorphoSys Reaches Clinical Milestone with Pfizer25 January 2011
Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers24 January 2011
Spectrum Pharmaceuticals Submits Data to FDA in Support of Bioscan Removal for ZEVALIN21 January 2011
NewLink Genetics to Present Phase 2 Data of Its HyperAcute Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium21 January 2011
FibroGen Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic Cancer21 January 2011
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium21 January 2011
Immunomedics Reports Targeted Therapy for Advanced Pancreatic Cancer Improves Survival20 January 2011
Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells19 January 2011
Peregrine Announces Initiation of Investigator-Sponsored Trial in HER2-Negative Metastatic Breast Cancer19 January 2011
Merck Serono: Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOXNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports